Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection.

@article{McIntosh2015PreventionOR,
  title={Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection.},
  author={E David G McIntosh and Victor Carey and Daniela Toneatto and Peter M. Dull and James Wassil},
  journal={Therapeutic advances in vaccines},
  year={2015},
  volume={3 1},
  pages={13-23}
}
In countries with established programmes for vaccination of infants, toddlers and adolescents with meningococcal conjugate vaccines, serogroup B invasive meningococcal disease remains the major cause of septicaemia and meningitis in the paediatric and adolescent age groups. Novartis has developed a serogroup B meningococcal vaccine, 4CMenB, to meet this need. We reviewed all 4CMenB studies. The studies found 4CMenB to be highly immunogenic when administered in all schedules, with protective… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 69 references

isolates and estimated coverage of the 4CMenB meningococcal vaccine

  • T. Vesikari, S. Esposito, R. Prymula, E. Ypma, I. Kohl, D Toneatto
  • BMC Microbiol
  • 2013
Highly Influential
5 Excerpts

infection and risk of invasive meningococcal disease in Central Ontario, Canada

  • G. e15493. Tzanakaki, E. Hong, K. Kesanopoulos, A. Xirogianni, S. Bambini, O Luca
  • PLoS One
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…